Latest news with #Thrombosis
Yahoo
07-08-2025
- Business
- Yahoo
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?
Viatris (VTRS), a global healthcare company, is scheduled to report second-quarter 2025 results on Aug. 7, 2025, before the bell. The Zacks Consensus Estimate for revenues is pegged at $3.50 billion, while the same for earnings is pinned at $0.56 per share. Factors to Consider for VTRS Q2 Earnings The company reports under four segments on the basis of geography — Developed Markets; Emerging Markets; Japan, Australia and New Zealand ('JANZ'); and Greater China. Growth in Developed Markets, driven by brands such as Creon, Brufen, and its Thrombosis portfolio, has likely boosted sales from this segment and offset the decline in generics. While sales from Europe have likely maintained growth, the same from North America have possibly been under pressure due to inspections in the manufacturing facility in Indore, India, and expected competition in the generic business. The Zacks Consensus Estimate for revenues from Developed Markets is pinned at $2.1 billion. Sales from Emerging Markets were under pressure in the first quarter due to the impact of the Indore facility and customer buying patterns on the generics business. Nonetheless, growth in brands across the cardiovascular portfolio in certain Latin American countries and continued strengths in the Middle East and North America and Eurasia regions have likely offset this impact in the second quarter. The Zacks Consensus Estimate for revenues from this geography is pegged at $542 million. Sales in JANZ are likely to have been adversely impacted by government-driven price regulations in Japan and Australia, as well as by a change in Japan's reimbursement for off-patent brands that accelerated generic conversion. The Zacks Consensus Estimate for revenues from the JANZ markets is pinned at $310 million. Sales in Greater China might have seen an increase due to the company's diversified model across e-commerce, retail, and private hospitals. The Zacks Consensus Estimate for revenues from this geography is pegged at $546 million. Viatris also reports revenues under two divisions (in terms of product category) — brands and generics. Brand business comprises the majority of the company's portfolio. Brand performance is likely to have benefited from the expansion of its cardiovascular portfolio in certain Latin American countries and strong growth in Europe and Greater China. Operating expenses might have risen during the quarter due to SG&A investments in new product launches and progress in key R&D programs. VTRS' Share Price Performance Viatris' shares have lost 29.3% in the past year compared with the industry's decline of 8.4%. Image Source: Zacks Investment Research VTRS' Mixed Earnings Surprise History The company's earnings beat estimates in three of the trailing four quarters and missed in the remaining one, delivering an average surprise of 2.14%. In the last reported quarter, VTRS beat on earnings by 2.04%. Viatris Inc. Price, Consensus and EPS Surprise Viatris Inc. price-consensus-eps-surprise-chart | Viatris Inc. Quote What Our Model Predicts for Viatris Our proven model does not conclusively predict an earnings beat for Viatris this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. Earnings ESP: VTRS has an Earnings ESP of 0.0% as both the Zacks Consensus Estimate and the Most Accurate Estimate are pinned at 56 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #3. Stocks to Consider Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around. Amneal Pharmaceuticals (AMRX) has an Earnings ESP of +13.21% and a Zacks Rank #2 at present. You can see the complete list of today's Zacks #1 Rank stocks here. Amneal beat on earnings in three of the trailing four quarters and missed in the remaining one, delivering an average surprise of 14.34%. AMRX is scheduled to report second-quarter results on Aug. 5. Exact Sciences (EXAS) has an Earnings ESP of +475.00% and a Zacks Rank #2 at present. Shares of EXAS have lost 16.4% year to date. It beat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 48.79%. Exact Sciences is expected to report second-quarter results on Aug. 6, after market close. Pfizer (PFE) has an Earnings ESP of +1.43% and a Zacks Rank #3 at present. The company is scheduled to release second-quarter results on Aug. 5. Higher sales of Pfizer's products like Vyndaqel family, Padcev, Lorbrena and Nurtec are expected to have offset softer sales of some key products like Prevnar, Xeljanz, Eliquis and Ibrance in the second quarter. PFE beat on earnings in each of the trailing four quarters, delivering an average surprise of 43.49%.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report AMNEAL PHARMACEUTICALS, INC. (AMRX) : Free Stock Analysis Report Viatris Inc. (VTRS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
News18
30-06-2025
- Health
- News18
Why Are Younger People Suffering More Heart Attacks Post-COVID?
Last Updated: Heart attacks are rising among young adults post-COVID, driven by hidden risks and lasting effects of the virus. In recent years, heart attacks among young adults have been on the rise—a shift that has become more pronounced since the COVID-19 pandemic. Once considered a disease of older age, cardiovascular events are now increasingly seen in younger individuals due to a mix of direct viral effects, lifestyle disruptions, and hidden health risks. While initially recognized as a respiratory illness, COVID-19 has since been shown to exert significant and lasting effects on the cardiovascular system. The virus promotes inflammation in blood vessels, increases blood coagulability, and can trigger spikes in blood pressure—mechanisms that elevate the risk of heart attacks, particularly in patients with existing but often undiagnosed conditions such as high LDL cholesterol, obesity, hypertension, and diabetes. Dr. Sarita Rao, Senior Interventional Cardiologist, Apollo Hospitals, shares all you need to know: Emerging evidence supports this growing concern. A large-scale study involving over 150,000 individuals with a history of COVID-19 infection found substantially increased risks of myocardial infarction, heart failure, arrhythmias, and stroke—even in those with no prior heart disease. A recent NIH-supported study published in Arteriosclerosis, Thrombosis, and Vascular Biology further revealed that people infected during the pandemic's first wave had double the risk of major cardiovascular events, with those hospitalized facing up to a fourfold increase. This elevated risk persisted for up to three years post-infection, often rivaling or exceeding traditional risk factors like diabetes. Although mild COVID-19 cases do not appear to significantly raise heart attack risk directly, the broader lifestyle and environmental consequences of the pandemic have had a substantial impact on young adults' cardiovascular health. Importantly, vaccination has emerged as a protective factor. Studies from multiple countries—including India, the U.S., South Korea, and the U.K.—have demonstrated that vaccinated individuals are less likely to suffer from acute cardiac complications, largely due to reduced illness severity and better preservation of lipid profiles. Ultimately, the rise in heart attacks among younger adults is not merely a consequence of COVID-19 but a reflection of deeper, multifactorial vulnerabilities that the pandemic has brought to the surface. The convergence of genetic predisposition, sedentary lifestyles, unhealthy diets, environmental exposures, and chronic stress has created fertile ground for early cardiovascular disease. COVID-19 has acted as both a trigger and an amplifier of these underlying risks. Addressing this growing crisis demands a comprehensive approach—one that includes early cardiovascular screening, preventive care, promotion of healthy behaviors, and robust public health interventions. As we move forward in the post-pandemic era, prioritizing heart health in younger populations is essential to reversing current trends and securing a healthier future. Dr. Sarita Rao, Senior Interventional Cardiologist & Director Cathlab, Apollo Hospitals Indore
NBC Sports
19-04-2025
- Sport
- NBC Sports
Pacers pull away early behind quality defense against Antetokounmpo, go on to take Game 1 114-97
Indiana is often thought of as a high-octane, up-tempo, top-10 offense in the NBA (which they are), but they also can defend. The Pacers were top-10 in the league after the All-Star break. Or, just ask Giannis Antetokounmpo and the Bucks. The Pacers' defense showed out Saturday in Game 1 against the Bucks. Indiana loaded up its defense on Giannis Antetokounmpo, was physical with him from the opening tip, and made him work hard for every bucket. While he still finished with 36 points on 14-of-23 shooting, Antetokounmpo couldn't run free, he never got his teammates going. The bigger problem for Milwaukee was that Antetokounmpo was the only guy creating or scoring for the Bucks: Kyle Kuzma was 0-of-5 shooting and finished without a point, Bobby Portis and Ryan Rollins each shot 2-of-8, and Kevin Porter Jr. was 2-of-7. The result was Indiana looking dominant early, leading by 28 points and never being seriously threatened on their way to a 117-98 win, taking a 1-0 series lead. Myles Turner steps back and CASHES. 🎯 Big-time 3 late in Game 1 on ESPN. Pascal Siakam led the Pacers with 25 points on 10-of-15 shooting, while Tyrese Haliburton added 10 points and 12 rebounds in the win. The key to the game, however, was the Pacers' defense. 'He's a tough cover…' Siakam said of Antetokounmpo. 'He's very good at getting to the paint. He's strong. He's physical. I thought we did a decent job but he did get a couple of easy baskets.' The Bucks have one big change for Game 2 — Damian Lillard could return from the deep vein Thrombosis that kept him out at the end of the season. Lillard was heard at Game 1, too, trash-talking Haliburton. Dame had words for Hali during timeout 👀🍿 That's all just white noise to the Pacers after their win. Myles Turner had 19 points for the Pacers and Andrew Nembhard added 17.
